NCT06996652View on ClinicalTrials.gov

An Exploratory Study of the Potential for Rational Immune System Manipulation to Prevent Emergence of Synucleinopathy Manifestations in Persons With REM Sleep Behavior Disorder (RBD)

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

108

Participants

Timeline

Start Date

September 30, 2025

Primary Completion Date

April 30, 2028

Study Completion Date

April 30, 2028

Conditions
REM Sleep Behavior Disorder
Interventions
DRUG

Adalimumab

40 mg self-administered subcutaneously using a pre-filled syringe (PFS) every 2 weeks for up to 2 years

DRUG

Placebo

40 mg matching placebo self-administered subcutaneously using a pre-filled syringe (PFS) every 2 weeks for up to 2 years

Trial Locations (1)

06473

Yale Medicine, North Haven

All Listed Sponsors
collaborator

The Marcus Foundation

OTHER

lead

Yale University

OTHER